.Pharmacolibrary.Drugs.ATC.L.L01BA01

Information

Methotrexate is an antimetabolite and antifolate drug used in the treatment of various cancers, including leukemia, lymphoma, and solid tumors, as well as autoimmune diseases like rheumatoid arthritis and psoriasis. It acts by inhibiting dihydrofolate reductase, preventing DNA synthesis, and cell replication. Methotrexate is approved and widely used in clinical practice.

Pharmacokinetics

Pharmacokinetic parameters reported in adult cancer patients after intravenous administration.

References

1. Nader, A, et al., & Wilby, KJ (2017). Population Pharmacokinetics of Intravenous Methotrexate in Patients with Hematological Malignancies: Utilization of Routine Clinical Monitoring Parameters. European journal of drug metabolism and pharmacokinetics 42(2) 221–228. DOI:10.1007/s13318-016-0338-1 PUBMED:https://pubmed.ncbi.nlm.nih.gov/27059845

2. Medellin-Garibay, SE, et al., & Romano-Moreno, S (2020). Population pharmacokinetics of methotrexate in Mexican pediatric patients with acute lymphoblastic leukemia. Cancer chemotherapy and pharmacology 85(1) 21–31. DOI:10.1007/s00280-019-03977-1 PUBMED:https://pubmed.ncbi.nlm.nih.gov/31673826

3. Shi, ZY, et al., & Yan, D (2020). Population pharmacokinetics of high-dose methotrexate in Chinese pediatric patients with medulloblastoma. Biopharmaceutics & drug disposition 41(3) 101–110. DOI:10.1002/bdd.2221 PUBMED:https://pubmed.ncbi.nlm.nih.gov/32017134

Revisions

• 06/2025 initial generated model